# EDGAR Filing Document

**Accession Number:** 0001474322
**File Stem:** 0001628280-26-033820
**Filing Date:** 2026-5
**Character Count:** 9600
**Document Hash:** 11be74dfd05b81c333a00e2572f25fdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-033820.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001628280-26-033820

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260206

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tansey Casey M
- **CENTRAL INDEX KEY:** 0001474322

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43275
- **FILM NUMBER:** 26965460

**MAIL ADDRESS:**
- **STREET 1:** 1460 EL CAMINO REAL STE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mobia Medical, Inc.
- **CENTRAL INDEX KEY:** 0001489993
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208573833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2802 FLINTROCK TRACE, SUITE 226
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** (855) 628-9375

**MAIL ADDRESS:**
- **STREET 1:** 2802 FLINTROCK TRACE, SUITE 226
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MicroTransponder, Inc.
- **DATE OF NAME CHANGE:** 20100420

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tansey Casey M<br><sub>(Last) (First) (Middle)</sub><br>2802 FLINTROCK TRACE, SUITE 226<br><sub>(Street)</sub><br>AUSTIN, TX 78738<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Mobia Medical, Inc. [ MOBI ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-11 |  | C |  | 166666 | A | <sup>(1)</sup> | 166666 | D |  |
| Common Stock | 2026-05-11 |  | P |  | 66666 | A | $15 | 233332 | D |  |
| Common Stock | 2026-05-11 |  | C |  | 314090 | A | <sup>(1)</sup> | 314090 | I | See Footnote<sup>(2)(3)(4)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 3312736 | A | <sup>(5)</sup> | 3626826 | I | See Footnote<sup>(2)(3)(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Convertible Notes | <sup>(1)</sup> | 2026-02-06<sup>(6)</sup> |  | A |  | 3769090.08 |  | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 314090 | $3769090.08 | 3769090.08 | I | By U.S. Venture Partners Select Fund I, L.P |
| Convertible Notes | <sup>(1)</sup> | 2026-02-10<sup>(6)</sup> |  | A |  | 2000000 |  | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 166666 | $2000000 | 2000000 | D |  |
| Stock Option | $15 | 2026-05-07 |  | A |  | 31520 |  | <sup>(7)</sup> | 2026-05-07 | Common Stock | 31520 | $0 | 31520 | D |  |
| Convertible Notes | <sup>(1)</sup> | 2026-05-11 |  | C |  |  | 3769090.08 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 314090 | <sup>(1)</sup> | 0 | I | By U.S. Venture Partners Select Fund I, L.P |
| Convertible Notes | <sup>(1)</sup> | 2026-05-11 |  | C |  |  | 2000000 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 166666 | <sup>(1)</sup> | 0 | D |  |
| Series F Preferred Stock | <sup>(5)</sup> | 2026-05-11 |  | C |  |  | 5642738 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1620078 | <sup>(5)</sup> | 0 | I | See Footnote<sup>(2)(3)(4)</sup> |
| Series E-2 Preferred Stock | <sup>(5)</sup> | 2026-05-11 |  | C |  |  | 5895530 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1692658 | <sup>(5)</sup> | 0 | I | See Footnote<sup>(2)(3)(4)</sup> |

---

### Footnotes:

(1) The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.

(2) After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock  held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds").

(3) Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A.

(4) The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

(5) Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms.

(6) This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a).

(7) The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.

**Signature:** /s/ Chase Leavitt, Attorney-in-Fact  
**Date:** 2026-05-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**